TY - JOUR
T1 - Strategies for large-scale expansion of clinical-grade human multipotent mesenchymal stromal cells
AU - García-Fernández, Coral
AU - López-Fernández, Alba
AU - Borrós, Salvador
AU - Lecina, Martí
AU - Vives, Joaquim
N1 - Funding Information:
Work in our laboratories is supported by the Spanish Cell Therapy Network (TerCel , expedient No. RD16/0011/0028), and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational program ( European Regional Development Fund ) 2014-2020. JV’s laboratory is awarded by the Generalitat de Catalunya as Consolidated Research Group (ref. 2017SGR719) and funded with project PI19/01788 by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF) - A way to build Europe.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/7/15
Y1 - 2020/7/15
N2 - Production of sufficient numbers of multipotent Mesenchymal Stromal Cells is a great challenge that the industry must address to meet the increasing demand for clinical size product batches. This can be understood as an opportunity to exploit existing bioprocessing technologies already tested successfully in the production of vaccines and biologicals. Herein we analyse the transition from traditional manual cell expansion 2D methodologies to scalable and automated platforms with the capacity to yield billions of cells per batch in a robust, reproducible and cost-effective manner in compliance with current Good Manufacturing Practices. This review gives special relevance to the key features of multiple manufacturing platforms, particularly those using microcarriers to support cell expansion and single-use bioreactors.
AB - Production of sufficient numbers of multipotent Mesenchymal Stromal Cells is a great challenge that the industry must address to meet the increasing demand for clinical size product batches. This can be understood as an opportunity to exploit existing bioprocessing technologies already tested successfully in the production of vaccines and biologicals. Herein we analyse the transition from traditional manual cell expansion 2D methodologies to scalable and automated platforms with the capacity to yield billions of cells per batch in a robust, reproducible and cost-effective manner in compliance with current Good Manufacturing Practices. This review gives special relevance to the key features of multiple manufacturing platforms, particularly those using microcarriers to support cell expansion and single-use bioreactors.
KW - Expansion culture platforms
KW - Good manufacturing practices
KW - Logistics
KW - Multipotent mesenchymal stromal cell
KW - Scale up
KW - Single-use bioreactors
UR - http://www.scopus.com/inward/record.url?scp=85084610009&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000537604100017&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.bej.2020.107601
DO - 10.1016/j.bej.2020.107601
M3 - Review
AN - SCOPUS:85084610009
SN - 1369-703X
VL - 159
JO - Biochemical Engineering Journal
JF - Biochemical Engineering Journal
M1 - 107601
ER -